Skip to main content

Catalyst Calendar

Tue, Sep 29, 2026

1 updates

8:00 AM

Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher

atossatherapeutics.com

Thu, Sep 24, 2026

1 updates

8:00 AM

Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging

atossatherapeutics.com

Fri, Aug 7, 2026

1 updates

8:45 AM

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Enrollment • Phase 2Enrollment completion Tue, Jun 30, 2026atossatherapeutics.com

Tue, Jul 28, 2026

1 updates

8:30 AM

Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer

atossatherapeutics.com

Tue, Jul 21, 2026

1 updates

8:30 AM

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

atossatherapeutics.com